• 提示：詳情請下載說明書。

• 產(chǎn)品描述： Esonarimod is an antirheumatic drug.

• 靶點(diǎn)： IL Receptor;ILReceptor

• 體內(nèi)研究：
  After repeated oral administration of Esonarimod (14C-KE-298), the radioactivity decreases rapidly and no tendency towards accumulation is found

• 細(xì)胞實(shí)驗(yàn)： For in vitro experiment, Esonarimod (KE-298) is dissolved in ethanol and diluted with culture medium or distilled water.RAW264.7 cells are used in this study. For NO production, RAW264.7 cells [2×105/0.2 mL of RPMI-1640 supplemented by 10% heat inactivated fetal bovine serum (FBS), penicillin G (100 U/mL), and streptomycin (100 μg/mL)] are stimulated with 100 ng/mL of Escherichia coli 026:B6 lipopolysaccharide in the presence of Esonarimod (KE-298) (0, 10, 30, 100, 200, 300 μg/mL) in 96 well plates and incubated 24 h at 37°C in an atmosphere of 5% CO2 in air. After incubation, the supernatants are collected and assayed for nitrite (NO2-) instead of NO

• 動物實(shí)驗(yàn)： Seven-week-old male Wistar rats is administered Esonarimod (5 mg/kg once daily) orally by gastric intubation

• 參考文獻(xiàn)：
  1.Inoue T, et al. KE-298 and its active metabolite KE-758 suppress nitric oxide production by murine macrophage cells and peritoneal cells from rats with adjuvant induced arthritis. J Rheumatol. 2001 Jun;28(6):1229-37. 2.Hasegawa M, et al. Formation of a disulfide protein conjugate of the SH-group-containing metabolite (M-I) ofesonarimod (KE-298) and its elimination in rats. J Pharm Pharmacol. 2002 Apr;54(4):493-8.

• 溶解性： DMSO:10  mM

• 保存條件： 2-8℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	3.567 ml	17.836 ml	35.671 ml
  5 mM	0.713 ml	3.567 ml	7.134 ml
  10 mM	0.357 ml	1.784 ml	3.567 ml
  50 mM	0.071 ml	0.357 ml	0.713 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *